TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.66% | 23.82% | 3.64% | 9.81% | -5.59% |
| Total Depreciation and Amortization | 3.48% | 35.95% | 92.88% | 215.01% | 424.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 212.06% | 114.84% | 255.72% | 115.01% | 162.24% |
| Change in Net Operating Assets | 67.51% | -274.87% | -135.92% | -207.73% | -182.69% |
| Cash from Operations | 26.22% | 3.52% | 10.96% | -7.17% | -14.67% |
| Capital Expenditure | 38.76% | 66.61% | 78.04% | 68.11% | 64.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 38.76% | 66.61% | 78.04% | 68.11% | 64.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.09% | -31.04% | 96.79% | 1,663.00% | 265,056.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Financing | 3.09% | -32.06% | 102.13% | 1,663.00% | 265,056.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 238.29% | -316.94% | 97.79% | 121.61% | 86.12% |